Pharmacies told to stop making custom versions of Wegovy and Zepbound after shortages declared officially over ...

T he US Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk are now in an attempt to making more ...

The global pharmaceutical industry could generate about $1.2 trillion in sales in 2025, according to Statista, and projections call for 4.7% annual growth through 2029. The cancer treatment segment ...

Suspicious Ozempic products should be reported to Novo Nordisk or directly to the FDA. In addition, any adverse effects from ...

Which European healthcare stocks are most attractive right now? Seeking Alpha analysts offer their picks. Read more here.

Novo Nordisk (NYSE: NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

Americans shelled out an estimated $71 billion for weight-loss drugs in 2023 - that is as much as the U.S. government disbursed in foreign aid the same year, according to ForeignAssistance.gov.

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Both the FDA and Novo Nordisk are advising patients and providers to check their supplies of Ozempic for counterfeit product. Individuals in possession of a counterfeit product are urged to call Novo ...